News | May 21, 2010

Delivery System Makes for More Precise Stent Placement

May 21, 2010 – A new stent delivery system is designed to be reliable, easy to use and precise when delivering the self-expanding Supera peripheral vascular stent. The new delivery system was launched this week in Europe.

The Supera Veritas system was developed to deliver the Supera for the treatment of biliary and peripheral artery disease (PAD).

“We have been utilizing the Supera stent clinically for more than two years and we are very impressed with the performance of the stent and positive clinical outcomes,” said Dierk Scheinert, M.D., chairman of the Center for Vascular Medicine at the Park Hospital Leipzig, Germany. "With the new Supera Vertas delivery system, we now have a more effective tool for the smooth and controlled deployment of the Supera stent. It significantly reduces the number of steps needed to prep and deliver the stent, all of which greatly increase its ease of use and accuracy.”

The IDEV Inc. expects to introduce two additional products in its family of Supera stents by the end of this year. The stent uses an interwoven self-expanding nitinol design. It has U.S. Food and Drug Administration (FDA) 510(k) clearance for palliative treatment for biliary strictures produced by malignant neoplasms. It is currently the focus of a prospective, FDA-approved, single-arm clinical trial of 258 patients at up to 40 sites in the United States.

For more information:

Related Content

First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init